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After peripheral nerve injury, a process of axonal degradation, debris clearance, and subsequent regeneration is initiated by
complex local signaling, called Wallerian degeneration (WD). This process is in part mediated by neuroglia as well as infiltrating
inflammatory cells and regulated by inflammatory mediators such as cytokines, chemokines, and the activation of transcription
factors also related to the inflammatory response. Part of this neuroimmune signaling is mediated by the innate immune
system, including arachidonic acid (AA) derivatives such as prostaglandins and leukotrienes. The enzymes responsible for
their production, cyclooxygenases and lipooxygenases, also participate in nerve degeneration and regeneration. The interactions
between signals for nerve regeneration and neuroinflammation go all the way down to the molecular level. In this paper, we discuss
the role that AA derivatives might play during WD and nerve regeneration, and the therapeutic possibilities that arise.
1. Introduction
Nerve injury can occur at any point along the length of
a peripheral nerve as it courses from the root through
the plexus and then to the target organ. There are a
number of mechanisms whereby peripheral nerves may be
directly traumatized, including compression, traction, drug
injection, and laceration, toxins, ischemia, infection, and
physical agents. The principal target of peripheral nerve
injury is the axon. Injury may also aﬀect specialized neuronal
sheath cells called Schwann cells (SCs), which are intimately
associated with all peripheral nerve axons. Irrespective of
cause, there is a limited range of responses to peripheral
nerve injury of which the most important is Wallerian
degeneration (WD).
WD is a sequential pattern of axonal degeneration,
myelin degradation, and supporting glial cell proliferation
lasting 24–48 h. During this complex process, various
events take place, including blood-nerve barrier dysfunction,
endoneural space reorganization [1], and most importantly
for our purposes, the induction of an intense inflammatory
response, constituted by inflammatory mediator release and
production [2]. Axonal degeneration initiates this response,
activating SC and macrophages, that prolipherate and acti-
vate, clearing myelin debris and producing cytokines that
perpetuate an inflammatory state. Axonal regeneration is
then regulated by the interactions between all the involved
cell types and by cytokines, chemokines, growth factors, and
other inflammatorymediators [2]. All these events culminate
in the promotion of an environment suitable for subsequent
regeneration, repair, and axon regrowth.
Arachidonic acid (AA) and its metabolites are known
to modulate neuronal function and survival. There is also
evidence that AA derivatives, such as prostaglandins (PG),
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leukotrienes, and the enzymes involved in their production,
such as cyclooxygenases (COX), lipooxygenases (LOX),
among others, are centrally involved in WD and in axonal
regeneration [2]. In this paper we will discuss the available
evidence that sheds light in this issue.
2. Phospholipases and AA
Phospholipases (PL) are ubiquitous in mammalian cells and
serve to cleave free fatty acids from cell membrane phospho-
lipids. AA is one such fatty acid, and itself a precursor for
eicosanoids. PLs are known to be upregulated in neurons
weeks after crush injury to peripheral nerves, indicating
increased protein synthesis involved in regeneration [3]. PLA
has been hypothesized to participate in neuronal membrane
disruption after injury, via lypolisis, DNA fragmentation,
and lipid peroxidation, through a calcium-dependent mech-
anism [4, 5].
PLA is expressed in the nerve crush site as well as
in resident and infiltrating macrophages, suggesting a role
for PLA in myelin breakdown, a vital process during WD
[6]. PLAD1 immunoreactivity is also increased in SCs and
macrophages in sciatic nerves, using a rat model of exper-
imental neuritis [7]. Recent evidence has established that
PLA2 initiates the breakdown of compact myelin through
macrophage interactions and participates in chemokine and
cytokine expression after nerve injury [8]. PLs are also
known to participate in the molecular signaling of SC
morphology and proliferation [9], and immortalized SCs
show increased PLC activity [10]. PLC alpha shows a similar
pattern of increased expression during the first days after
axonal injury, while PLC beta-1 expression is reduced in
the same setting [11], pointing to diﬀerent functions and
dynamics of PLs. In keeping with these results, knockout
and pharmacological inhibition studies have established
specific roles for diﬀerent PLA2 families during WD. The
calcium-independent group VIA participates in the early
stages of myelin breakdown, while the calcium-dependent
group IVA participates in myelin clearance and phagocytosis
by macrophages [12]. However, the accumulated evidence
leaves little doubt of the participation of PL during nerve
degeneration/regeneration.
The role of PLA2 during axonal regeneration was
further clarified in studies showing that PLA2 inhibitors
diminish neuron outgrowth after axonal injury, and that
PLA2 activators seem to promote it [13]. Similar findings
were described in brain noradrenergic injured neurons,
where PLA2 activators could induce axonal regeneration
[14]. Coupled with evidence of PLA2 expression in growth
cones, this evidence points toward a local role for PLA in
nerve regeneration. PLA also participates during degener-
ation. Mutant mice with impaired WD do not show PLA
expression in injured nerves, while mutant mice with PLA
deficiencies show diminished myelin and axonal degrada-
tion and phagocytosis [15]. Additionally, whereas increased
expression of PLA is common in peripheral nerve after
injury, the same is not evident after injury to the optic nerve,
which correlates to slow WD in the central nervous system
(CNS).
AA itself has been found to posses trophic and toxic
eﬀects both in hippocampal neurons and in chick motoneu-
rons in vitro, possibly trough a LOX pathway [16, 17]. AA
can also participate in neurite growth trough a calcium-
dependent mechanism [18].
There is another potential mechanism by which PL and
AA contribute to the pathophysiology of nerve degeneration.
The oxidative metabolism of AA is known to result in the
production of free radicals and in lipid peroxidation. These
processes are partly responsible for the initial local damage
induced by acute injury in nerve tissue, due to the rich
lipid content of myelin sheats. The full implication of this
association remains to be elucidated.
3. COX
COXs catalyze the conversion of AA to PGs and throm-
boxanes, which trigger as autocrine and paracrine chemical
messengers in many physiological and pathophysiological
responses [19]. The COXs exist in two isoforms, a consti-
tutive form (COX-1) and an inducible form (COX-2), and
a COX-1 splice variant termed as COX-3 has been reported
[20]. COX-1 and -2 share the same substrates, produce
the same products, and catalyze the same reaction using
identical catalytic mechanisms [21, 22]. The COX-1 enzyme
is expressed in most tissues and is responsible for main-
taining homeostasis (gastric and renal integrity) and normal
production of PGs. COX-2 is predominantly found in brain,
kidney, and endothelial cells and is significantly upregu-
lated as part of various acute and chronic inflammatory
conditions. COX-2 expression can be induced in response
to growth factors, cytokines, and proinflammatory stimuli.
Moreover, COX-2 has been implicated in the regulation of
the inflammatory response that occurs during WD, both
directly and by way of their products, eicosanoids.
After nerve injury, COX-2 expression is locally upreg-
ulated, but this phenomenon has been mainly linked to
the pathogenesis of neuropathic pain [23, 24], although
COX-1 could also participate in tissue remodeling during
WD in the spinal cord [25]. Both COX-1 and COX-2
expression is increased in macrophages and SCs in animal
models of inflammatory demyelinating diseases [7]. The
administration of COX inhibitors obstruct myelin debris
signals that negatively aﬀect axonal regeneration after injury,
resulting in increased axonal regeneration in vitro, and COX
inhibitors can also aﬀect SC and macrophage phagocytic
activity [26, 27]. In a recent paper, we reported accelerated
functional recovery after sciatic nerve crush in rats treated
with celecoxib, a selective COX-2 inhibitor, thereby directly
implicating COX-2 in nerve regeneration [28].
4. Eicosanoids
After nerve injury, increased COX expression induces the
production of PG in nerve terminals and nonneural cells
in the surrounding areas, a process that is known to
induce hyperalgesia and neuropathic pain [23, 29]. PGs
are produced in important quantities, and for prolonged
time periods, both directly by injured nerves, as well as
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by macrophages in response to soluble factors produced
by injured nerves [30]. Prostanoid receptors, eﬀectors of
biological actions of PG, have been shown to be expressed
in SCs, and to be able to modulate SC function in vivo
[31]. Additionally, studies have demonstrated that PGE2 is
able to modulate microglial migration and function [32].
Prostanoids have also been shown to interact with nerve
growth factor in the regulation of inflammatory responses
and degeneration after tissue injury [33]. Coupled with the
pivotal roles that microglia play during WD and regenera-
tion, a role for PGs in nerve degeneration and regeneration
after injury is beginning to be recognized.
PG are vasoactive molecules, and their contribution
to blood-flow homeostasis and inflammation during nerve
injury could be important. Alprostadil, a PGE1 analogue,
diminishes peripheral nerve ischemia-reperfusion injury,
probably through such a mechanism [34]. Other mech-
anisms are involved during nerve repair, however. After
nerve crush injury, alprostadil treatment results not only
in reduced injury, but also in increased repair rates and
in the upregulation of vascular endothelial growth fac-
tor, itself known to be neuroprotective [35]. PGD2, a
potent inflammatory mediator, shows increased expression
inmacrophages after spinal cord injury, and both PGD2 inhi-
bition and PGD2 knockout result in improved locomotor
function [36].
The induction of neuronal apoptosis after nerve injury
is an established phenomenon that contributes to the
physiopathology of nerve degeneration. The administration
of PGE1 inhibits neuronal apoptosis in the spinal cord after
sciatic nerve constriction injury, independently of changes in
local blood flow [37]. This suggests a mechanism not solely
dependent on vasoactive properties of PG. Further studies
also showed that not only does PGE1 reduce apoptosis
but also improves neuronal regeneration after sciatic nerve
crush injury [38]. Latanoprost, a PGF2 analogue, could
also reduce retinal ganglion cell apoptosis after optic nerve
crush [39, 40]. This evidence supports the idea that PGs are
neuroprotective through the inhibition of apoptosis.
The mechanisms by which PGs modulate nerve regener-
ation seem to be quite complex. PGs are known to modulate
the upregulation of heat-shock protein-70 expression, a
protein response known to participate in the maintenance
of neuron survival after nerve injury [41, 42]. After nerve
injury, macrophages migrate into the area and initiate
degenerative and regenerative processes. PGE2 has been
demonstrated tomodulate the production of interleukin-6 in
invading macrophages after nerve injury, a cytokine known
to participate both in nerve degeneration and regeneration
[2, 43]. In the central nervous system, PGA1 is neuro-
protective against injury through a variety of mechanisms,
such as blockade of the proinflammatory transcription
factor nuclear factor κappa B (NF-κB) and upregulation
of peroxisome proliferator-activated receptor-gamma [44].
Considering the important role of NF-κB in peripheral nerve
degeneration and regeneration, this mechanism could be
biologically relevant [2].
Much evidence exists to support the idea that beyond
hyperalgesia and blood-flow regulation, PGs also contribute
to the molecular and cellular process of nerve degeneration
and regeneration. However, current knowledge is limited,
and the exact mechanisms are just being uncovered.
5. LOX
LOX and its metabolites are known to participate in the
physiopathology of many disorders in the central nervous
system and in acute inflammatory disorders [45], but they
also play a role in neurite growth, an essential step in
axonal regeneration. Leukotrienes are produced in injured
nerves and regulate neuropathic pain in a similar fashion
as in the case of PGs [46], and SCs produce leukotrienes
in response to inflammatory signaling [47]. Hepoxilin A3
(HxA3), is a 12-lipoxygenase metabolite of AA, found in the
mammalian nervous system, and has been proposed to play
a global role in calcium regulation [48]. Hepoxilin enhances
neurotrophin-dependent neurite regeneration in cultured
axotomized neurons, possibly through the modulation of
intracellular calcium, which plays a crucial role in neurite
outgrowth during development and regeneration, including
gene expression, cytoskeleton assembly, and growth cone
formation [49, 50]. Axonal injury also induces PLA activity
through a calcium-dependent mechanism, and leukotrienes
result as second messengers that control growth cone
formation [51]. In fact, both leukotriene antagonists and
PLA inhibitors result in delayed neurite outgrowth and
function in cultured neurons [52]. Leukotriene B4 induces
the diﬀerentiation of neural stem cells into neurons that
actively produce neurite outgrowth [53]. Together these
findings implicate LOX metabolites in the process of axonal
regeneration.
6. AA-Associated Neuroinflammation
and Regeneration Signaling at the
Molecular Level
Neurons in the peripheral nervous system (PNS) respond
to injury through gene expression in an appropriate
regeneration-prone environment as well [54]. The mediators
of these dynamics are transcription factors and their net-
works, that act as orchestrators of gene expression according
to intrinsic nerve regeneration programs. This is thought
to be the fundamental diﬀerence between CNS and PNS
neurons in terms of regenerating capacity. Considering the
complexity of these processes, it is no surprise that they
interact and sometimes merge with the same signaling that
mediates inflammation after PNS injury.
Activating transcription factor 3 (ATF3) is a stress-
inducible transcription factor known to be induced after
injury in neurons, and a regulator of neuron growth in
its constitutive from as well. COX inhibition is known to
alter the expression of ATF3 in human colorectal carcinoma
cells and thus inhibit growth [55]. Signal transducer and
activator of transcription 3 (STAT3) is activated in response
to growth factors, cytokines, and hormones that are known
to play protective role after nerve injury and to mediate
nerve regeneration [54]. COX-1 deficient mice show reduced
4 The Scientific World Journal
SC
SC
SC
SC
Injury
Nerve
degeneration/regeneration
↑ COX-1
↑ COX-2
↑ LOX
↑ Phospholypases
Prostaglandins
Lenkotrienes
+Neuroinflammation
±NRAGs
Figure 1: Proposed theoretical framework. After nerve injury, AA derivatives produced in neurons and microglia participate in nerve
degeneration and regeneration, through local, remote, and molecular pathways. Injury promotes SC infiltration and activation as well as
phospholipase, COX and LOX upregulation with the ensuing production of eicosanoids. These signals promote degeneration initially and
later regulate the regenerative process. NRAGs are in turn heavily influenced by these signals. SC: Schwann cell; NRAGs: nerve regeneration
associated genes; LOX: lipooxygenases; COX: cyclooxygenases.
Table 1: Clinically approved modulators of arachidonic acid derivatives.
Drug class COX inhibitors Eicosanoid analogues
LOX inhibitors
and leukotriene antagonists
Phospholipase
inhibitors
Examples
NSAIDS
Selective COX-2
inhibitors (celecoxib)
Misoprostol (PGE1)
Latanoprost (F2α)
Unoprostone (F2α)
Travoprost (F2α)
Iloprost (PGI2)
Epoprostenol (PGI2)
Zileuton
Zafirlukast
Montelukast
Quinacrine
Mepacrine
Chloroquine
Clinical
applications
Analgesic
Anti-inflammatory
Pulmonary hypertension
(iloprost, epoprostenol)
Glaucoma (latanoprots,
unoprostone)
Asthma, allergic rhinitis,
urticaria
Antiprotozoal
Antirheumatic
Antimalarial
Routes of
administration
Oral, parenteral Inhaled, parenteral, topical Oral Oral
Notes
Zafirlukast and
Montelukast are cysteinyl
leukotriene receptor
CysLT1 antagonists
NSAID: nonsteroidal anti-inflammatory drugs; PGI: prostacyclin.
neuroinflammatory and microglial responses to insults,
through reduced activation of both Nf-κB and STAT3
[56]. PGE2 is known to regulate the activation of STAT3,
and PGE2 inhibition alters a signal required for dendritic
cell survival and development, leading to apoptosis [57].
Survivin, a regulator of cell survival, is regulated by COX-2-
generated PGE2 in part trough a STAT3 pathway [58]. PGE2
also mediates survival of nonneural cells, such as myocytes,
through a STAT3 pathway [59].
The phosphoinositide 3-kinase (PI3K) and the mitogen-
activated protein kinase (MAPK) pathways are activated in
injured neurons, and act as intracellular cascades that modu-
late regeneration associated genes. Indomethacin treatment
in tumor cells has been shown to decrease expression of
PI3K [60]. Latanoprost, the synthetic derivative of PGF2a,
is able to promote retinal ganglion cell survival and promote
neurite outgrowth through a PGF receptor-mediated mod-
ulation of the PI3K pathway [61]. PI3K inhibition leads to
enhanced protsnoids production in activated microglia, and
additionally, PI3K can regulate the expression of COX-2 in
microglia as a response to neuroinflammation [62]. MAPK
pathways are involved in neuroinflammation in many ways,
including the enhancement of sensory neuron interleukin-
6 production [63] and the regulation of interleukin-1-
mediated COX-2 expression [64]. Latanoprost also uses a
MAPK pathway in order to rescue nuroglial cells from
apoptosis [65].
Specificity protein-1 (Sp1) is a transcription machinery
theorized to act as a general regulator of many of the
nerve injury-inducible transcription factors, including some
discussed above [54]. COX inhibitors are also known to
alter Sp1 phosphorylation and lead to arrested cell growth
in tumor cells [66], and PGE2 can stimulate cell growth
through induction of Sp1 DNA-binding activity [67]. PGE2
enhances the phosphorylation, DNA binding, and transcrip-
tional activity of Sp1, and it leads to enhanced neurotrophin
production through a Sp1 pathway [68], suggesting a
possible mechanism for PGE2-induced reinnervation.
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Table 2: Selected animal and human therapeutic studies.
Reference
number
Model Intervention Outcome
[26] Spinal cord injury in rats
Indomethacin and ibuprofen (COX
inhibitors)
Increased functional recovery and
axonal regeneration
[28] Sciatic nerve crush in rats Celecoxib (COX2 inhibitor) Improved functional recovery
[38] Sciatic nerve crush in diabetic rats PGE1 Improved axonal regeneration
[37] Sciatic nerve constriction injury in rats PGE agonist Decreased neuronal apoptosis
[35] Sciatic nerve injury in rats Alprostadil (PGE)
Decreased injury and improved
functional recovery
[34]
Sciatic nerve ischemia-reperfusion
injury in rats
Alprostadil Decreased injury
[69]
Carpal tunnel syndrome. Human
clinical trial
Tenoxicam (COX inhibitor)
No beneficial eﬀects compared to
placebo
These finding illustrate the complex interactions between
inflammatory and neuroregenerative signaling. Further-
more, these mechanisms could partly enlighten some of the
ways AA derivatives might further regulate the regeneration-
prone environment and suggest additional strategies in
order to modulate neuroinflammation, and therefore, nerve
survival after injury.
7. Therapeutic Possibilities
The use of COX inhibitors for posttraumatic neuropathic
pain is an established therapeutical intervention. However,
given the association that exists between AA derivatives
and nerve degeneration and regeneration, the therapeutic
modulation of this pathway emerges as a novel strategy
aimed at increased motor, sensory, and structural recovery
after nerve injury. We summarize some of the potential
mechanisms involved in Figure 1. Currently, COX inhibitors,
LOX inhibitors, PG analogues, among other drugs, are
approved for human use in clinical situations (Table 1).
The development of phospholipase modulators and other
drugs targeting AA derivatives is an active field of research,
which will soon clarify the validity of this therapeutic
strategy.
The dual function of AA derivatives, as promoters
and inhibitors of nerve degeneration and recovery, will
complicate the clinical application of these drugs. It is
becoming evident that the dual role of neuroinflammation
as both injurious and as a promoter of regeneration is a
complex one, even at the molecular level. It is most likely
that a combination approach will be fruitful, using com-
pounds that optimize regeneration and others that diminish
degeneration. The exact time of administration will also
be important, since some of these molecules are expressed
early after injury, while others begin to be produced in
the late stages after regeneration. Additionally, although the
evidence reviewed here concerns primarily peripheral nerve
injury, most of the concepts could be applied both to spinal
cord and CNS injury. In conclusion, the findings reviewed
here point toward a new avenue in the pharmacological
treatment of nerve injury, based on a pathophysiologically
relevant paradigm (Table 2). The numerous compunds that
exist today suggest that clinical studies are warranted.
Conflict of Interests
The authors declare no conflict of interests.
References
[1] P. Dubovy´, “Wallerian degeneration and peripheral nerve
conditions for both axonal regeneration and neuropathic pain
induction,” Annals of Anatomy, vol. 193, no. 4, pp. 267–275,
2011.
[2] C. R. Ca´mara-Lemarroy, F. J. Guzma´n-de la Garza, and N.
E. Ferna´ndez-Garza, “Molecular inflammatory mediators in
peripheral nerve degeneration and regeneration,” NeuroIm-
munoModulation, vol. 17, no. 5, pp. 314–324, 2010.
[3] M. Alberghina and A. M. Giuﬀrida Stella, “Changes
of phospholipid-metabolizing and lysosomal enzymes in
hypoglossal nucleus and ventral horn motoneurons during
regeneration of craniospinal nerves,” Journal of Neurochem-
istry, vol. 51, no. 1, pp. 15–20, 1988.
[4] A. A. Farooqui, H. C. Yang, and L. Horrocks, “Involvement
of phospholipase A2 in neurodegeneration,” Neurochemistry
International, vol. 30, no. 6, pp. 517–522, 1997.
[5] P. K. Stys, “General mechanisms of axonal damage and its
prevention,” Journal of the Neurological Sciences, vol. 233, no.
1-2, pp. 3–13, 2005.
[6] J. A. Paul and N. A. Gregson, “An immunohistochemical study
of phospholipase A2 in peripheral nerve during Wallerian
degeneration,” Journal of Neuroimmunology, vol. 39, no. 1-2,
pp. 31–48, 1992.
[7] T. Shin, Y. Lee, and K. B. Sim, “Involvement of cyclooxygenase-
1 and -2 in the sciatic nerve of rats with experimental
autoimmune neuritis,” Immunological Investigations, vol. 32,
no. 3, pp. 123–130, 2003.
[8] R. Martini, S. Fischer, R. Lo´pez-Vales, and S. David, “Interac-
tions between Schwann cells and macrophages in injury and
inherited demyelinating disease.,” Glia, vol. 56, no. 14, pp.
1566–1577, 2008.
[9] L. N. Berti-Mattera, S. Harwalkar, B. Hughes, P. L. Wilkins,
and K. Almhanna, “Proliferative and morphological eﬀects of
endothelins in Schwann cells: roles of p38 mitogen-activated
6 The Scientific World Journal
protein kinase and Ca2+-independent phospholipase A2,”
Journal of Neurochemistry, vol. 79, no. 6, pp. 1136–1148, 2001.
[10] L. N. Berti-Mattera, P. L.Wilkins, S. Harwalkar, Z.Madhun, K.
Almhanna, and R. Mattera, “Endothelins regulate arachidonic
acid release and mitogen-activated protein kinase activity in
Schwann cells,” Journal of Neurochemistry, vol. 75, no. 6, pp.
2316–2326, 2000.
[11] T. Saika, H. Kiyama, T. Matsunaga, and M. Tohyama, “Diﬀer-
ential regulation of phospholipase C isozymes in the rat facial
nucleus following axotomy,” Neuroscience, vol. 59, no. 1, pp.
121–129, 1994.
[12] R. Lo´pez-Vales, X. Navarro, T. Shimizu et al., “Intracellular
phospholipase A2 group IVA and group VIA play important
roles in Wallerian degeneration and axon regeneration after
peripheral nerve injury,” Brain, vol. 131, pp. 2620–2631, 2008.
[13] A. Edstro¨m, M. Briggman, and P. A. Ekstro¨m, “.Phospholipase
A2 activity is required for regeneration of sensory axons in
cultured adult sciatic nerves,” Journal of Neuroscience Research,
vol. 43, pp. 183–189, 1996.
[14] S. Nakamura, “Involvement of phospholipase A2 in axonal
regeneration of brain noradrenergic neurones,” NeuroReport,
vol. 4, no. 4, pp. 371–374, 1993.
[15] S. De, M. A. Trigueros, A. Kalyvas, and S. David, “Phospho-
lipase A2 plays an important role in myelin breakdown and
phagocytosis during wallerian degeneration,” Molecular and
Cellular Neuroscience, vol. 24, no. 3, pp. 753–765, 2003.
[16] S. Okuda, H. Saito, and H. Katsuki, “Arachidonic acid:
toxic and trophic eﬀects on cultured hippocampal neurons,”
Neuroscience, vol. 63, no. 3, pp. 691–699, 1994.
[17] F. Dehaut, I. Bertrand, T. Miltaud, A. Pouplard-Barthelaix,
and M. Maingault, “n-6 Polyunsaturated fatty acids increase
the neurite length of PC12 cells and embryonic chick
motoneurons,” Neuroscience Letters, vol. 161, no. 2, pp. 133–
136, 1993.
[18] E. J. Williams, F. S. Walsh, and P. Doherty, “The production of
arachidonic acid can account for calcium channel activation in
the second messenger pathway underlying neurite outgrowth
stimulated by NCAM, N-cadherin, and L1,” Journal of Neuro-
chemistry, vol. 62, no. 3, pp. 1231–1234, 1994.
[19] R. G. Kurumbail, J. R. Kiefer, and L. J. Marnett, “Cyclooxy-
genase enzymes: catalysis and inhibition,” Current Opinion in
Structural Biology, vol. 11, no. 6, pp. 752–760, 2001.
[20] T. D. Warner and J. A. Mitchell, “Cyclooxygenase-3 (COX-
3): filling in the gaps toward a COX continuum?” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 99, no. 21, pp. 13371–13373, 2002.
[21] K. Gupta, B. S. Selinsky, C. J. Kaub, A. K. Katz, and P. J. Loll,
“The 2.0 a resolution crystal structure of prostaglandin H2
synthase-1: structural insights into an unusual peroxidase,”
Journal of Molecular Biology, vol. 335, no. 2, pp. 503–518, 2004.
[22] R. M. Garavito and A. M. Mulichak, “The structure of
mammalian cyclooxygenases,” Annual Review of Biophysics
and Biomolecular Structure, vol. 32, pp. 183–206, 2003.
[23] W. Ma and J. C. Eisenach, “Morphological and pharmaco-
logical evidence for the role of peripheral prostaglandins in
the pathogenesis of neuropathic pain,” European Journal of
Neuroscience, vol. 15, no. 6, pp. 1037–1047, 2002.
[24] W. Ma and R. Quirion, “Does COX2-dependent PGE2 play a
role in neuropathic pain?” Neuroscience Letters, vol. 437, no. 3,
pp. 165–169, 2008.
[25] J. M. Schwab, K. Brechtel, T. D. Nguyen, and H. J.
Schluesener, “Persistent accumulation of cyclooxygenase-1
(COX-1) expressing microglia/macrophages and upregulation
by endothelium following spinal cord injury,” Journal of
Neuroimmunology, vol. 111, no. 1-2, pp. 122–130, 2000.
[26] Q. Fu, J. Hue, and S. Li, “Nonsteroidal anti-inflammatory
drugs promote axon regeneration via RhoA inhibition,”
Journal of Neuroscience, vol. 27, no. 15, pp. 4154–4164, 2007.
[27] A. Klegeris and P. L. McGeer, “Cyclooxygenase and 5-
lipoxygenase inhibitors protect against mononuclear phago-
cyte neurotoxicity,” Neurobiology of Aging, vol. 23, no. 5, pp.
787–794, 2002.
[28] C. R. Ca´mara-Lemarroy, F. J. Guzma´n-de la Garza, E. A.
Barrera-Oranday, A. J. Cabello-Garcı´a, A. Garcı´a-Tamez, and
N. E. Ferna´ndez-Garza, “Celecoxib accelerates functional
recovery after sciatic nerve crush in the rat,” Journal of Brachial
Plexus and Peripheral Nerve Injury, vol. 3, article 25, 2008.
[29] J. P. Syriatowicz, D. Hu, J. S. Walker, and D. J. Tracey,
“Hyperalgesia due to nerve injury: role of prostaglandins,”
Neuroscience, vol. 94, no. 2, pp. 587–594, 1999.
[30] N. Muja and G. H. DeVries, “Prostaglandin E2 and 6-keto-
prostaglandin F1α production is elevated following traumatic
injury to sciatic nerve,” Glia, vol. 46, no. 2, pp. 116–129, 2004.
[31] N. Muja, J. K. Nelson, and G. H. DeVries, “Schwann cells
express IP prostanoid receptors coupled to an elevation in
intracellular cyclic AMP,” Journal of Neuroscience Research, vol.
85, no. 6, pp. 1159–1169, 2007.
[32] S. Kunori, S. Matsumura, E. Okuda-Ashitaka et al., “A novel
role of prostaglandin E2 in neuropathic pain: blockade of
microglial migration in the spinal cord,” Glia, vol. 59, no. 2,
pp. 208–218, 2011.
[33] J. S. Marshall, K. Gomi, M. G. Blennerhassett, and J.
Bienenstock, “Nerve growth factor modifies the expression
of inflammatory cytokines by mast cells via a prostanoid-
dependent mechanism,” Journal of Immunology, vol. 162, no.
7, pp. 4271–4276, 1999.
[34] A. Milcan, E. Arslan, O. T. Bagdatoglu et al., “The eﬀect of
alprostadil on ischemia-reperfusion injury of peripheral nerve
in rats,” Pharmacological Research, vol. 49, no. 1, pp. 67–72,
2004.
[35] J. Tang, Y. Hua, J. Su et al., “Expression of VEGF and neural
repair after alprostadil treatment in a rat model of sciatic nerve
crush injury,” Neurology India, vol. 57, no. 4, pp. 387–394,
2009.
[36] A. Redensek, K. I. Rathore, J. L. Berard et al., “Expression and
detrimental role of hematopoietic prostaglandin D synthase in
spinal cord contusion injury,” Glia, vol. 59, no. 4, pp. 603–614,
2011.
[37] T. Kawamura, T. Akira, M. Watanabe, and Y. Kagitani,
“Prostaglandin E1 prevents apoptotic cell death in superficial
dorsal horn of rat spinal cord,” Neuropharmacology, vol. 36,
no. 8, pp. 1023–1030, 1997.
[38] S. Kogawa, H. Yasuda, M. Terada, K. Maeda, and R. Kikkawa,
“Apoptosis and impaired axonal regeneration of sensory
neurons after nerve crush in diabetic rats,” NeuroReport, vol.
11, no. 4, pp. 663–667, 2000.
[39] H. Kudo, T. Nakazawa, M. Shimura et al., “Neuroprotective
eﬀect of latanoprost on rat retinal ganglion cells,” Graefe’s
Archive for Clinical and Experimental Ophthalmology, vol. 244,
no. 8, pp. 1003–1009, 2006.
[40] A. Kanamori, M. Naka, M. Fukuda, M. Nakamura, and A.
Negi, “Latanoprost protects rat retinal ganglion cells from
apoptosis in vitro and in vivo,” Experimental Eye Research, vol.
88, no. 3, pp. 535–541, 2009.
[41] H. S. Sharma and J. Westman, “Prostaglandins modulate
constitutive isoform of heat shock protein (72 kD) response
The Scientific World Journal 7
following trauma to the rat spinal cord,” Acta Neurochirurgica,
Supplement, vol. 1997, no. 70, pp. 134–137, 1997.
[42] G. A. Newfry and K. J. Jones, “Diﬀerential eﬀects of facial
nerve transection on heat shock protein 70 expression in the
developing and adult hamster facial nucleus,” Metabolic Brain
Disease, vol. 13, no. 3, pp. 253–257, 1998.
[43] W. Ma and R. Quirion, “Up-regulation of interleukin-6
induced by prostaglandin E2 from invading macrophages
following nerve injury: an in vivo and in vitro study,” Journal
of Neurochemistry, vol. 93, no. 3, pp. 664–673, 2005.
[44] H. L. Zhang, Z. L. Gu, S. I. Savitz, F. Han, K. Fukunaga,
and Z. H. Qin, “Neuroprotective eﬀects of prostaglandin
A1 in rat models of permanent focal cerebral ischemia are
associated with nuclear factor-κB inhibition and peroxisome
proliferator-activated receptor-γ up-regulation,” Journal of
Neuroscience Research, vol. 86, no. 5, pp. 1132–1141, 2008.
[45] J. W. Phillis, L. A. Horrocks, and A. A. Farooqui, “Cyclooxy-
genases, lipoxygenases, and epoxygenases in CNS: their role
and involvement in neurological disorders,” Brain Research
Reviews, vol. 52, no. 2, pp. 201–243, 2006.
[46] K. Noguchi and M. Okubo, “Leukotrienes in nociceptive
pathway and neuropathic/inflammatory pain,” Biological &
Pharmaceutical Bulletin, vol. 34, pp. 1163–1169, 2011.
[47] A. L. Constable, P. J. Armati, and H. P. Hartung, “DMSO
induction of the leukotriene LTC4 by Lewis rat Schwann cells,”
Journal of the Neurological Sciences, vol. 162, no. 2, pp. 120–
126, 1999.
[48] C. R. Pace-Asciak, “Hepoxilins: a review on their cellular
actions,” Biochimica et Biophysica Acta, vol. 1215, no. 1-2, pp.
1–8, 1994.
[49] V. Rehder, J. R. Jensen, and S. B. Kater, “The initial stages of
neural regeneration are dependent upon intracellular calcium
levels,” Neuroscience, vol. 51, no. 3, pp. 565–574, 1992.
[50] N. E. Ziv and M. E. Spira, “Localized and transient elevations
of intracellular Ca2+ induce the dediﬀerentiation of axonal
segments into growth cones,” Journal of Neuroscience, vol. 17,
no. 10, pp. 3568–3579, 1997.
[51] M. S. Geddis and V. Rehder, “Initial stages of neural regenera-
tion in Helisoma trivolvis are dependent upon PLA2 activity,”
Journal of Neurobiology, vol. 54, no. 4, pp. 555–565, 2003.
[52] N. R. Smalheiser, S. Dissanayake, and A. Kapil, “Rapid regula-
tion of neurite outgrowth and retraction by phospholipase A2-
derived arachidonic acid and its metabolites,” Brain Research,
vol. 721, no. 1-2, pp. 39–48, 1996.
[53] K. Wada, M. Arita, A. Nakajima et al., “Leukotriene B4
and lipoxin A4 are regulatory signals for neural stem cell
proliferation and diﬀerentiation,” FASEB Journal, vol. 20, no.
11, pp. 1785–1792, 2006.
[54] S. Kiryu-Seo and H. Kiyama, “The nuclear events guiding
successful nerve regeneration,” Frontiers in Molecular Neuro-
science, vol. 4, article 53, 2011.
[55] F. G. Bottone, J. M. Martinez, B. Alston-Mills, and T. E. Eling,
“Gene modulation by Cox-1 and Cox-2 specific inhibitors in
human colorectal carcinoma cancer cells,” Carcinogenesis, vol.
25, no. 3, pp. 349–357, 2004.
[56] S. H. Choi, R. Langenbach, and F. Bosetti, “Genetic deletion
or pharmacological inhibition of cyclooxygenase-1 attenuate
lipopolysaccharide-induced inflammatory response and brain
injury,” FASEB Journal, vol. 22, no. 5, pp. 1491–1501, 2008.
[57] P. Singh, J. Hoggatt, P. Hu et al., “Blockade of prostaglandin
E2 signaling through EP1 and EP3 receptors attenuates Flt3L-
dependent dendritic cell development from hematopoietic
progenitor cells,” Blood, vol. 119, pp. 1671–1682, 2012.
[58] K. S. Chun and R. Langenbach, “The prostaglandin E2 recep-
tor, EP2, regulates survivin expression via an EGFR/STAT3
pathway in UVB-exposed mouse skin,” Molecular Carcinogen-
esis, vol. 50, no. 6, pp. 439–448, 2011.
[59] M. A. Frias, S. Somers, C. Gerber-Wicht, L. H. Opie, S. Lecour,
and U. Lang, “The PGE2-Stat3 interaction in doxorubicin-
induced myocardial apoptosis,” Cardiovascular Research, vol.
80, no. 1, pp. 69–77, 2008.
[60] H. Axelsson, C. Lo¨nnroth, M. Andersson, and K. Lundholm,
“Mechanisms behind COX-1 and COX-2 inhibition of tumor
growth in vivo,” International Journal of Oncology, vol. 37, no.
5, pp. 1143–1152, 2010.
[61] J. Zheng, X. Feng, L. Hou et al., “Latanoprost promotes
neurite outgrowth in diﬀerentiated RGC-5 cells via the
PI3K-Akt-mTOR signaling pathway,” Cellular and Molecular
Neurobiology, vol. 31, no. 4, pp. 597–604, 2011.
[62] A. C. de Oliveira, E. Candelario-Jalil, J. Langbein et al.,
“Pharmacological inhibition of Akt and downstream pathways
modulates the expression of COX-2 andmPGES-1 in activated
microglia,” Journal of Neuroinflammation, vol. 9, article 2,
2012.
[63] B. St-Jacques and W. Ma, “Role of prostaglandin E2 in the
synthesis of the pro-inflammatory cytokine interleukin-6 in
primary sensory neurons: an in vivo and in vitro study,”
Journal of Neurochemistry, vol. 118, no. 5, pp. 841–854, 2011.
[64] A. S. Moolwaney and O. J. Igwe, “Regulation of the
cyclooxygenase-2 system by interleukin-1β through mitogen-
activated protein kinase signaling pathways: a comparative
study of human neuroglioma and neuroblastoma cells,”
Molecular Brain Research, vol. 137, no. 1-2, pp. 202–212, 2005.
[65] Y. Nakanishi, M. Nakamura, H. Mukuno, A. Kanamori, G. M.
Seigel, and A. Negi, “Latanoprost rescues retinal neuro-glial
cells from apoptosis by inhibiting caspase-3, which is mediated
by p44/p42 mitogen-activated protein kinase,” Experimental
Eye Research, vol. 83, no. 5, pp. 1108–1117, 2006.
[66] A. Kambe, H. Yoshioka, H. Kamitani, T. Watanabe, S. J.
Baek, and T. E. Eling, “The cyclooxygenase inhibitor sulindac
sulfide inhibits EP4 expression and suppresses the growth of
glioblastoma cells,” Cancer Prevention Research, vol. 2, no. 12,
pp. 1088–1099, 2009.
[67] Y. Zheng, J. D. Ritzenthaler, X. Sun, J. Roman, and S.
Han, “Prostaglandin E2 stimulates human lung carcinoma
cell growth through induction of integrin-linked kinase: the
involvement of EP4 and Sp1,” Cancer Research, vol. 69, no. 3,
pp. 896–904, 2009.
[68] N. Kanda, S. Koike, and S. Watanabe, “Prostaglandin E2
enhances neurotrophin-4 production via EP3 receptor in
human keratinocytes,” Journal of Pharmacology and Experi-
mental Therapeutics, vol. 315, no. 2, pp. 796–804, 2005.
[69] M. H. Chang, H. T. Chiang, S. S. J. Lee, L. P. Ger, and Y. K. Lo,
“Oral drug of choice in carpal tunnel syndrome,” Neurology,
vol. 51, no. 2, pp. 390–393, 1998.
Submit your manuscripts at
http://www.hindawi.com
Neurology 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Alzheimer’s Disease
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Scientifica
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
Schizophrenia
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Neural Plasticity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
Autism
Sleep Disorders
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Neuroscience 
Journal
Epilepsy Research 
and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Psychiatry 
Journal
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Depression Research 
and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Brain Science
International Journal of
Stroke
Research and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Neurodegenerative 
Diseases
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Cardiovascular Psychiatry 
and Neurology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
